WBR0110
| Author | [[PageAuthor::William J Gibson (Reviewed by Yazan Daaboul, M.D. and Rim Halaby, M.D. [1])]] |
|---|---|
| Exam Type | ExamType::USMLE Step 1 |
| Main Category | MainCategory::Genetics |
| Sub Category | SubCategory::Cardiology, SubCategory::Musculoskeletal/Rheumatology |
| Prompt | [[Prompt::A 16-year-old male adolescent presents to his pediatrician for the evaluation of scoliosis. During physical examination, the physician notes that in addition to his scoliosis, the patient is tall and has an increased arm span-to-height ratio, with a chest wall deformity (shown below). Also, he has crowded teeth and dental malocclusion. The physician calculates the patient's metacarpal index in the clinic and is found to be more than 8. The physician suspects a genetic origin for the patient’s condition. Which of the following may potentially be used to treat this patient’s condition?
|
| Answer A | AnswerA::Losartan |
| Answer A Explanation | [[AnswerAExp::Angiotensin receptor blockers have been shown to be useful in patient’s with Marfan syndrome.]] |
| Answer B | AnswerB::Lisinopril |
| Answer B Explanation | AnswerBExp::ACE-inhibitors are used for hypertension and diabetic renal disease. |
| Answer C | AnswerC::Hydrochlorothiazide |
| Answer C Explanation | [[AnswerCExp::Hydrochlorothiazide is a thiazide diuretic which is used to treat hypercalciuria and nephrogenic diabetes insipidus.]] |
| Answer D | AnswerD::Spironolactone |
| Answer D Explanation | [[AnswerDExp::Spironolactone is a potassium sparing diuretic and a competitive aldosterone receptor antagonist. It has antiandrogenic side effects.]] |
| Answer E | AnswerE::Furosemide |
| Answer E Explanation | [[AnswerEExp::Furosemide is a loop diuretic used in the treatment of congestive heart failure and edema.]] |
| Right Answer | RightAnswer::A |
| Explanation | [[Explanation::Marfan syndrome is an autosomal dominant genetic disorder primarily affecting connective tissue with variable expression. Skeletal malformations are the hallmark of Marfan syndrome; patients tend to be unusually tall, with long limbs and long, thin fingers, and hyperextensible joints. Characteristically, patients have lower segments of the body greater than the upper segments and increased arm span-to-height ratio. Additionally, patients may have chest wall abnormalities, such as pectus excavatum (as shown in the patient's image) or carinatum, that may require surgical intervention. Dental abnormalities described among patients with Marfan syndrome usually include crowded teeth and dental malocclusion. Classically, patients with Marfan syndrome also have oular manifestations, most specifically bilateral, symmetrical, and upward ectopia lentis (lens sublaxation)
Most patients with Marfan syndrome are diagnosed incidentally during a routine physical examination or at presentation for a Marfan-associated complication. The most serious complications are abnormalities of the cardiovascular system, especially defects of of the heart valves, such as mitral valve prolapse, and of the aorta, such as aortic dissection and root dilatation. The syndrome is carried by the gene FBN1, which encodes the connective protein fibrillin-1. Fibrillin-1 protein is essential for the proper formation of the extracellular matrix, including the biogenesis and maintenance of elastin fibers. In addition to being a connective protein that forms the structural support for tissues outside the cell, the normal fibrillin-1 protein binds to a cytokine called transforming growth factor beta (TGF-β). TGF-β signaling has deleterious effects on vascular smooth muscle development and the integrity of the extracellular matrix. Fibrillin-1 directly binds a latent form of TGF-β, keeping it sequestered and unable to exert its biological activity. It is now believed that secondary to mutated fibrillin, excessive TGF-β accumulation in the lungs, heart valves, and aorta weaken the tissues and cause the features of Marfan syndrome. Because angiotensin receptor blockers such as losartan block TGF-β activity, they have been used to treat Marfan Syndrome with some efficacy. |
| Approved | Approved::Yes |
| Keyword | WBRKeyword::Marfan, WBRKeyword::Marfan's syndrome, WBRKeyword::Pharmacology, WBRKeyword::Vascular, WBRKeyword::Connective tissue, WBRKeyword::Autosomal dominant, WBRKeyword::Genetics |
| Linked Question | Linked:: |
| Order in Linked Questions | LinkedOrder:: |
